BEBT-503

N/A

Report date: 2025/02/24 11:37:46
NME

Base Information

Drug NameBEBT-503
Drug Alias NameBEBT-503
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPeroxisome proliferator activated receptor agonists
TargetsPeroxisome proliferator activated receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver DiseaseCholangitis, Sclerosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesGuangzhou BeBetter Medicine Technology Co
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangzhou BeBetter Medicine Technology Co
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Metabolic Dysfunction-Associated Steatotic Liver DiseaseCholangitis, Sclerosing
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A